Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
KAF156 - Plasmodium Falciparum Inhibitor - PfCARL
mediated
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
Target Patients
Read-out Milesstone(s)
Publication
NCT03167242 (CKAF156A2202)
Malaria
Phase 2
PCR-corrected adequate clinical and parasitological response (ACPR)
KAF156 and LUM-SDF (different combinations)
Coartem
Adults and children with uncomplicated Plasmodium Falciparum Malaria
H2-2021
Two posters accepted, ASTMH meeting Nov 15-19 2020
Kublin JG et al. Clinical Infectious Diseases 09 Jul 2020, PMID: 32644127
133 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation